Prognostic Value of Drinking Status and Aldehyde Dehydrogenase 2 Polymorphism in Patients With Head and Neck Squamous Cell Carcinoma

Access this Article

Search this Article

Author(s)

    • Kawakita Daisuke
    • Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute|Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences
    • Matsuo Keitaro
    • Department of Epidemiology, Nagoya University Graduate School of Medicine|Division of Molecular Medicine, Aichi Cancer Center Research Institute
    • Oze Isao
    • Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute
    • Hosono Satoyo
    • Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute
    • Ito Hidemi
    • Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute
    • Watanabe Miki
    • Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute
    • Yatabe Yasushi
    • Department of Pathology and Molecular Diagnosis, Aichi Cancer Center Hospital
    • Murakami Shingo
    • Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences
    • Tanaka Hideo
    • Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute|Department of Epidemiology, Nagoya University Graduate School of Medicine

Abstract

<b>Background: </b>The association between alcohol drinking, aldehyde dehydrogenase 2 (<i>ALDH2</i>) polymorphism, and survival in patients with head and neck squamous cell carcinoma (HNSCC) remains unclear.<BR><b>Methods: </b>We performed a retrospective cohort study of 267 HNSCC patients at Aichi Cancer Center. Of these, 65 patients (24%) were non-drinkers, 104 (39%) were light drinkers (ethanol <46 g or <5 days/week), 46 (17%) were moderate drinkers (ethanol intake 46–68 g/day and ≥5 days/week), and 52 (20%) were heavy drinkers (ethanol intake ≥69 g and ≥5 days/week). The prognostic value of pre-treatment drinking status and <i>ALDH2</i> polymorphism was investigated using multivariate proportional hazard models.<BR><b>Results: </b>Drinking status was associated with disease-free survival (DFS) in HNSCC patients, with marginal statistical significance (5-year DFS: 67.9% [95% confidence interval {CI}, 53.8–78.4%] for non-drinkers, 57.6% [95% CI, 47.4–66.6%] for light drinkers, 46.1% [95% CI, 30.8–60.1%] for moderate drinkers, and 43.5% [95% CI, 29.3–56.9%] for heavy drinkers; <i>P</i> = 0.088). However, this association lost significance when multivariate analyses were adjusted for established prognostic factors. <i>ALDH2</i> genotype was not significantly associated with DFS in HNSCC patients (5-year DFS: 85.7% [95% CI, 53.9–96.2%] for Lys/Lys, 56.2% [95% CI, 47.4–64.1%] for Glu/Lys, and 50.5% [95% CI, 40.3–59.7%] for Glu/Glu; <i>P</i> = 0.154). After stratification by <i>ALDH2</i> genotype, we observed a significant positive dose-response relationship between drinking status and DFS in HNSCC patients with <i>ALDH2</i> Glu/Glu (<i>P</i><sub>trend</sub> = 0.029).<BR><b>Conclusions: </b>In this study, we identified a significant positive dose-response relationship between pre-treatment drinking status and DFS in HNSCC patients with <i>ALDH2</i> Glu/Glu. To confirm this association, further study is warranted.

Journal

  • Journal of Epidemiology

    Journal of Epidemiology 26(6), 292-299, 2016

    Japan Epidemiological Association

Codes

  • NII Article ID (NAID)
    130005154812
  • Text Lang
    ENG
  • ISSN
    0917-5040
  • Data Source
    J-STAGE 
Page Top